曲普瑞林联合小剂量生长激素物治疗女童CPP疗效及对骨龄的影响

摘要 目的：探讨曲普瑞林联合小剂量生长激素物治疗女童CPP疗效及对骨龄影响。方法：选取2017年1月至2020年1月我院收治的200例CPP女童,随机将其分为两组,对照组100例,给予常规治疗,研究组100例,给予曲普瑞林联合小剂量生长激素治疗。观察两组患者的临床疗效、治疗前后血清性激素水平、子宫容积、卵巢容积变化情况以及生长发育指标变化。结果：治疗后,研究组总有效率为98 %;显著高于对照组总有效率（80 %,P＜0.05）。两组FSH、LH、E₂水平、子宫容积、卵巢容积均降低,骨龄、身高、PAH均显著升高,且研究组上述指标明显优于对照组（P<0.05）。结论：曲普瑞林联合小剂量生长激素物治疗女童CPP疗效显著,能很好的改善患者血清性激素水平、子宫容积、卵巢容积,对生长发育指标具有积极的意义,值得临床推广和应用。     

NF-kB 拮抗剂PDTC 对HepG2 细胞的抑制及对caspase-3 表达的影响

目的:研究NF-kB拮抗剂PDTC诱导人肝癌HepG2细胞凋亡及其对凋亡相关基因caspase-3表达的影响,初步探讨其诱导凋亡的可能机制。方法:以不同浓度的PDTC处理人肝癌HepG2细胞,利用MTT法检测对人肝癌HepG2细胞凋亡的影响;利用RT-PCR和Western-blot检测caspase-3mRNA和蛋白的表达。结果:不同浓度PDTC作用人肝癌HepG2细胞不同时间后,能够显著抑制HepG2细胞的生长增殖,存在剂量和时间依赖性(P<0.05);PDTC能够上调HepG2细胞中caspase-3mRNA和蛋白的表达。结论:NF-kB拮抗剂PDTC对人肝癌HepG2细胞产生显著抑制,并能上调HepG2细胞中caspase-3mRNA和蛋白的表达。     

NF-kB拮抗剂PDTC对HepG2细胞的抑制及对caspase-3表达的影响

目的：研究NF-kB拮抗剂PDTC诱导人肝癌HepG2细胞凋亡及其对凋亡相关基因caspase-3表达的影响,初步探讨其诱导凋亡的可能机制。方法：以不同浓度的PDTC处理人肝癌HepG2细胞,利用MTT法检测对人肝癌HepG2细胞凋亡的影响;利用RT-PCR和Western-blot检测caspase-3mRNA和蛋白的表达。结果：不同浓度PDTC作用人肝癌HepG2细胞不同时间后,能够显著抑制HepG2细胞的生长增殖,存在剂量和时间依赖性（P〈0.05）;PDTC能够上调HepG2细胞中caspase-3mRNA和蛋白的表达。结论：NF-kB拮抗剂PDTC对人肝癌HepG2细胞产生显著抑制,并能上调HepG2细胞中caspase-3mRNA和蛋白的表达。     

三氧化二砷对肝癌细胞系SMMC-7721凋亡及 Smac caspase-9、caspase-3 蛋白表达的影响

目的：研究三氧化二砷（As203）对人肝癌细胞SMMC-7721的促凋亡作用及对Smac、caspase-9、caspase-3表达的影响。方法：人肝癌细胞SMMC-7721经As20,处理,共分为四组,分别为空白对照组、低剂量组、中等剂量组、高剂量组。分别采用MTT、Hoechst33258染色法、Annexin V-FITC／PI双染法观察其对SMMC．7721细胞增殖的抑制,凋亡细胞核的形态学变化,以及诱导凋亡作用;采用Westemblot法检测凋亡相关蛋白Smac、caspase-9、caspase-3表达的变化。结果：MTT显示：As203在体外能明显抑制SMMC-7721的生长,具有时间剂量依赖关系,与空白对照组相比,其余三组细胞生存率明显下降,差异均有统计学意义（P〈0．05）;Hoechst33258显示细胞呈明显的凋亡细胞形态学特征,具有剂量依赖性;AnnexinV-FITC／PI双染法显示：As203作用24小时可诱导SMMC-7721细胞凋亡,且呈剂量依赖性,与空白对照组相比（2．69±0．58）,其余三组（4．01±0．58）、（5．99±1．69）、（9．26±2．34）差异均有统计学意义（P〈0．05）;Westernblot显示：As2O3作用SMMC-7721细胞24小时,Smac、caspase-9、caspase-3表达上升,呈剂量依赖性,与空白对照组相比,其余三组蛋白表达量明显增加,差异均有统计学意义（P〈0．05）。结论：-定量的As203能抑制SMMC-7721细胞增殖,促进其凋亡,其机制可能与调控Smac、caspase-9、caspase-3表达有关。     

顺铂对小鼠耳蜗螺旋神经节细胞凋亡及caspase-3表达的影响

目的:建立小鼠顺铂(CDDP)耳毒性模型,研究不同剂量顺铂对小鼠耳蜗螺旋神经节细胞凋亡及caspase-3表达的影响。方法:采用末端脱氧核苷酸转移酶介导的缺口末端标记(TUNEL)技术检测螺旋神经节细胞的凋亡;应用免疫组织化学Envision法检测caspase-3在螺旋神经节中的表达;同时结合听脑干反应(ABR)测试,观察用药前后小鼠听力的变化。结果:不同剂量顺铂组小鼠体重和听力明显下降,与对照组比较均有显著性差异(P0.05,P0.01);并且随着顺铂给药剂量的增加,小鼠耳蜗螺旋神经节中TUNEL阳性细胞数增多,以及caspase-3表达明显增强。结论:应用小鼠能建立可靠的顺铂耳毒性模型;顺铂可导致耳蜗螺旋神经节细胞凋亡,而且此凋亡过程中有caspase-3的参与,进一步证实了凋亡可能是顺铂耳毒性机制之一。     

益坤宁对围绝经期大鼠卵巢细胞凋亡率及caspase-3表达的影响

目的:研究中药益坤宁(yikunning,YKN)对围绝经期大鼠卵巢细胞凋亡率及凋亡相关基因caspase-3基因表达的影响,探讨益坤宁治疗围绝经期综合征的作用机理。方法:选用30只自然衰老的围绝经期雌性大鼠,随机分为中药益坤宁实验组、围绝经期对照组和利维爱(livial)对照组,另选10只青年雌性大鼠作为青年对照组。连续灌胃处理4周后,采用原位脱氧核糖核苷酸末端转移酶介导的缺口末端标记(TUNEL)法检测大鼠卵巢细胞凋亡率,采用逆转录-聚合酶链反应(RT-PCR)和蛋白印迹(Western blot)检测大鼠卵巢中caspase-3 mRNA和蛋白表达。结果:益坤宁组大鼠卵巢细胞凋亡率显著低于围绝经期对照组(P0.01);益坤宁组大鼠卵巢中caspase-3 mRNA和蛋白表达低于围绝经期对照组,高于青年对照组,差异有统计学意义(P0.01)。结论:中药益坤宁通过降低围绝经期大鼠卵巢细胞凋亡率,下调卵巢中凋亡相关基因caspase-3的表达,从而延缓卵巢衰老,这可能是其治疗围绝经期综合征的分子机制之一。     

姜黄素对大鼠脑缺氧缺血损伤时脑组织MDA变化、caspase-3表达及细胞凋亡的影响

目的:探讨姜黄素对大鼠脑缺氧缺血损伤时脑组织MDA变化、caspase-3表达及细胞凋亡的影响。方法:健康SD雄性大鼠48只,随机分为假手术对照组(SH组)、脑缺氧缺血组(HI组)、姜黄素组(CU组)、溶剂对照组(SC组);生化方法检测脑组织丙二醛(MDA)含量;免疫组织化学测定大脑皮质caspase-3的表达;电镜观察大脑皮质形态学结构变化。结果:姜黄素可使脑组织MDA含量明显减低,并且抑制caspase-3蛋白的表达;神经元细胞凋亡减轻。结论:细胞凋亡参与了大脑缺氧缺血损伤的发生,姜黄素可能通过减低MDA含量、下调caspase-3的表达抑制细胞凋亡,从而减轻脑缺氧缺血性损伤。     

曲普瑞林对子宫肌瘤组织中MMP-13和TIMP-3表达的影响

目的:探讨曲普瑞林对子宫肌瘤患者肿瘤组织中MMP-13和TIMP-3表达影响。方法:选取我院收治的子宫肌瘤患者40例,随机分为两组,每组各20例。实验组予曲普瑞林后,行子宫肌瘤切除术,对照组直接行子宫肌瘤切除术,观察比较超声测量子宫和子宫肌瘤的体积,实时定量PCR法与免疫印迹法检测子宫肌层和肌瘤组织中MMP-13和TIMP-3的表达。结果:1与曲普瑞林治疗前以及对照组相比较,曲普瑞林治疗后临床症状显著改善,子宫和肌瘤体积均明显缩小,差异有统计学意义(P0.05)。2与对照组和治疗前相比较,血清雌二醇水平显著降低,差异有统计学意义(P0.05)。3与对照组相比较,肌层和肌瘤组织中MMP-13m RNA水平降低,肌层和肌瘤组织中TIMP-3m RNA水平增加,差异有统计学意义(P0.05)。结论:曲普瑞林能够通过降低血清雌二醇水平,降低肌层和肌瘤组织中MMP-3的表达,以及增加肌层和肌瘤组织中TIMP-13的表达,来缩小子宫和子宫肌瘤的体积,从而缓解患者的症状。     

GnRH脉冲模式对FSH分泌的影响

本文目的是进行GnRH脉冲模式对FSH分泌影响的研究。用GnRH以不同的脉冲振幅、不同的频率对GTH细胞进行刺激后,检测FSH的24 h分泌量。结果表明,FSH的24 h分泌量,以频率为120 min、振幅20 nmol/L时的GnRH脉冲模式为最高,并且随着GnRH刺激频率的增快或减慢,FSH的分泌量均呈逐渐减少趋势。所以,GnRH脉冲频率本身就是一个调控信号,不同脉冲频率GnRH对FSH表达有着明显不同的影响,在相同振幅条件下,低频脉冲刺激(120 min间隔)时FSH的分泌达到高峰。     

Effects of Luteolin on Human Breast Cancer Using Gene Expression Array: Inferring Novel Genes

Taraxacum officinale (dandelion) is often used in traditional Chinese medicine for the treatment of cancer; however, the downstream regulatory genes and signaling pathways mediating its effects on breast cancer remain unclear. The present study aimed to explore the effects of luteolin, the main biologically active compound of T. officinale, on gene expression profiles in MDA-MB-231 and MCF-7 breast cancer cells. The results revealed that luteolin effectively inhibited the proliferation and motility of the MDA-MB-231 and MCF-7 cells. The mRNA expression profiles were determined using gene expression array analysis and analyzed using a bioinformatics approach. A total of 41 differentially expressed genes (DEGs) were found in the luteolin-treated MDA-MB-231 and MCF-7 cells. A Gene Ontology analysis revealed that the DEGs, including AP2B1, APP, GPNMB and DLST, mainly functioned as oncogenes. The human protein atlas database also found that AP2B1, APP, GPNMB and DLST were highly expressed in breast cancer and that AP2B1 (cut-off value, 75%) was significantly associated with survival rate (p = 0.044). In addition, a Kyoto Encyclopedia of Genes and Genomes pathway analysis revealed that the DEGs were involved in T-cell leukemia virus 1 infection and differentiation. On the whole, the findings of the present study provide a scientific basis that may be used to evaluate the potential benefits of luteolin in human breast cancer. Further studies are required, however, to fully elucidate the role of the related molecular pathways.     

曲普瑞林对人乳腺癌细胞Fas/FasL基因表达的影响

为了观察GnRH激动剂曲普瑞林对人乳腺癌细胞生长的影响,探讨药物处理后细胞中Fas和Fas L基因的表达情况及其与细胞生长的关系,本研究采用了形态学显微镜观察、MTT检测和Real-time PCR技术,对曲普瑞林处理后乳腺癌细胞的生长增殖情况及Fas和Fas L基因表达的变化进行了研究。结果显示,曲普瑞林可抑制乳腺癌细胞MCF-7的生长并表现出了剂量依赖性,药物浓度越大对肿瘤细胞的抑制作用越强。随着药物浓度的增大、抑制作用增强,肿瘤细胞中Fas基因的表达量逐渐增大,而Fas L基因的表达量却逐渐下降。推测曲普瑞林在作用过程中可能通过促进肿瘤细胞中Fas的表达,诱导了Fas所介导的细胞凋亡途径的恢复,达到抑制肿瘤细胞生长的目的。     

Synthesis and Biological Evaluation of New GnRH Analogues on Pituitary and Breast Cancer Cells

GnRH analogues have been extensively used in oncology to induce reversible chemical castration due to their hypophysiotropic action. In addition to that, it has recently been shown that many malignant cells, such as breast cancer cells, locally produce GnRH and express the GnRH receptor/s. In order to investigate the structure-activity relationships in both pituitary and extrapituitary biological systems, we synthesized eight new GnRH analogues with modifications in the N-terminal part and/or in position 6 and studied their pituitary binding affinity (in αT3-1 cell membranes) and effect on breast cancer (MCF-7) cell proliferation. 2-Amino-4-pyrrolidinothieno[2,3-d]pyrimidine-6-carboxylic acid (ATPC) was incorporated instead of pGlu¹-His²- and/or Gly⁶ was substituted by α-aminoisobutyric acid, D-Leu and D-Lys (alone or covalently linked to Gly, Ala, Sar, ATPC). Most GnRH analogues lacked the carboxy-terminal Gly¹⁰-amide of GnRH and an ethylamide residue was added to Pro⁹, a modification common in many potent GnRH agonists, such as leuprolide ([D-Leu⁶, des-Gly¹⁰]-GnRH-NHEt. Results show differential impact of these modifications on the binding affinity to the GnRH receptor in mouse pituitary cells and on the inhibition of human breast cancer cell proliferation. ATPC in the N-terminus resulted in analogues with low binding affinity but high antiproliferative effect. Substitutions in position 6 always resulted in high binding affinities. In particular, [D-Lys⁶(Gly), desGly¹⁰]-GnRH-NHEt and [D-Lys⁶(Sar), desGly¹⁰]-GnRH-NHEt have higher pituitary binding affinity than leuprolide, but only the latter had significant antiproliferative effect on both MCF-7 and MDA-MB-231 cells. These results contribute to the on-going research for more potent GnRH analogues. Abbreviations of common amino acids are in accordance with the recommendations of IUPAC-IUB Joint Commission on Biochemical Nomenclature: Arch. Biochem. Biophys. 206, pp.v-xxii (1988), J. Biol. Chem. 264, 668–673 (1989) or J. Peptide Sci. 9, 1–8 (2003).     

SH3GL1在紫杉醇耐药乳腺癌中的表达及临床意义

膜结合蛋白SH3GL1参与调控某些肿瘤细胞生物学行为,而其对紫杉醇耐药乳腺癌细胞的恶性生物学行为影响尚未见报道.为阐明 SH3GL1对紫杉醇耐药敏感性的影响以及潜在的分子机制,本研究首先采用免疫组化法证实SH3GL1在紫杉醇耐药乳腺癌组织高表达(P<0.001).Western印迹法证实,SH3GL1在紫杉醇耐药细胞株MCF-7/PTX高表达(P<0.01);随后,采用MTT分别检测（0,50,100 nmol/L）紫杉醇处理后MCF-7细胞株增殖情况,同时Western印迹法检测SH3GL1表达,发现100 nmol/L紫杉醇能够抑制MCF-7细胞增殖(P<0.05);同时抑制SH3GL1表达(P<0.01); 敲减SH3GL1表达后,紫杉醇耐药细胞株MCF-7/PTX和MCF-7增殖速率降低(P<0.05),耐药基因MDR1表达降低(P<0.05),p-AKT和p-gp水平下降(P<0.05).上述结果表明,降低SH3GL1表达可以减弱紫杉醇耐药性,增加乳腺癌对紫杉醇的敏感性,这为临床上紫杉醇耐药乳腺癌患者的治疗提供了新的靶点.     

GSTs同工酶基因在乳腺癌中的扩增与基因的表达

采用ＤＮＡ和ＲＮＡ的斑点杂交分析方法,对３２例乳腺癌和相应的癌旁正常组织中ＧＳＴ－π、ＧＳＴ－α和ＧＳＴ－μ基因的ＤＮＡ扩增和ＲＮＡ转录表达情况进行研究,发现ＧＳＴ－π在乳腺癌中存在基因扩增和明显的ｍＲＮＡ表达升高,ＧＳＴ－π基因表达调控主要在转录水平进行的;ＧＳＴ－α和ＧＳＴ－μ在乳腺癌中表达水平较低,但仍可见α和μ类ＧＳＴ同工酶ｍＲＮＡ转录在肿瘤和正常组织中发生了较大的变化。结合乳腺癌中雌激素受体（ＥＲ）表达情况还发现ＧＳＴ－π表达水平与ＥＲ的表达存在负相关性。     

TrkB Promotes Breast Cancer Metastasis via Suppression of Runx3 and Keap1 Expression

In metastatic breast cancer, the acquisition of malignant traits has been associated with the increased rate of cell growth and division, mobility, resistance to chemotherapy, and invasiveness. While screening for the key regulators of cancer metastasis, we observed that neurotrophin receptor TrkB is frequently overexpressed in breast cancer patients and breast cancer cell lines. Additionally, we demonstrate that TrkB expression and clinical breast tumor pathological phenotypes show significant correlation. Moreover, TrkB expression was significantly upregulated in basal-like, claudin-low, and metaplastic breast cancers from a published microarray database and in patients with triple-negative breast cancer, which is associated with a higher risk of invasive recurrence. Interestingly, we identified a new TrkB-regulated functional network that is important for the tumorigenicity and metastasis of breast cancer. We demonstrated that TrkB plays a key role in regulation of the tumor suppressors Runx3 and Keap1. A markedly increased expression of Runx3 and Keap1 was observed upon knockdown of TrkB, treatment with a TrkB inhibitor, and in TrkB kinase dead mutants. Additionally, the inhibition of PI3K/AKT activation significantly induced Runx3 and Keap1 expression. Furthermore, we showed that TrkB enhances metastatic potential and induces proliferation. These observations suggest that TrkB plays a key role in tumorigenicity and metastasis of breast cancer cells through suppression of Runx3 or Keap1 and that it is a promising target for future intervention strategies for preventing tumor metastasis and cancer chemoprevention.     

Effect of GnRH analogs in postnatal domestic cats

The aim of this study was to reproductively assess the clinical and hormonal effects of a GnRH agonist (AG) and an antagonist (AN) administered during the postnatal period in domestic cats. Forty-eight male and female postnatal kittens were randomly assigned to deslorelin acetate 1.6 mg subcutaneous (AG; n = 16), acyline 33 μg/100 g subcutaneous weekly for 3 months (AN; n = 16), or control (CO; n = 16) which remained untreated. The cats were followed up (behavioral observation, physical examination, fecal sexual steroid determinations, mating test, and pregnancy diagnosis) up to puberty. Puberty was delayed (weeks) in the AG animals (62.9 ± 3.5; P < 0.01) but not in the AN (15.5 ± 1.7; P > 0.05) when they were compared with CO kittens (13.4 ± 0.4). Fifteen (15/16) of the AN and CO animals, and only 11 of 16 cats of the AG group were fertile (P > 0.1). No differences were found in body weight (P > 0.1) and measurements (P > 0.1), libido (P > 0.1) and in the appearance of side effects (P > 0.1; except a pyometra in an AG female) among groups. In both AG- and AN-treated males (testosterone; P < 0.01) and females (estradiol-17β; P < 0.01) fecal hormone concentrations were lower than in CO group during the first five postnatal weeks but not later. It is concluded that the neonatal administration of these AG and AN decreased fecal sexual steroids during the first postnatal weeks causing, the agonists but not the antagonist, a significant, reversible delay in puberty appearance.     

Inhibition of Human UDP-Glucose Dehydrogenase Expression Using siRNA Expression Vector in Breast Cancer Cells

UDP-glucose dehydrogenase (UGDH) catalyzes two oxidations of UDP-glucose to yield UDP-glucuronic acid. Pathological over-production of extracellular matrix components may be linked to the availability of UDP-glucuronic acid, therefore UGDH is a potential therapeutic target. RNA interference (RNAi) has been adapted to knock down the expression of human UGDH. A UGDH siRNA plasmid was constructed using a pRNA-U6.1/Neo vector and transfected into breast cancer cells, ZR-75-1, with an efficiency of up to 50%. Western blot analysis showed that the UGDH expression was efficiently knocked down at protein levels by RNAi in ZR-75-1 cells.